Last updated: September 7, 2026
Cisplatin is a mature, off-patent oncology medicine with low unit pricing, broad generic availability, and persistent supply-chain risk. Its financial trajectory is driven by treatment volume, hospital purchasing, API and sterile-injectable capacity, and shortage management rather than patent exclusivity. No biosimilar pathway applies because cisplatin is a small-molecule drug. Public companies generally do not disclose cisplatin revenue separately, so market value is best assessed through hospital demand, generic injectable pricing, procurement concentration, and supply continuity.
Cisplatin Market Dynamics, Financial Trajectory, Patents, and Generic Competition
What is cisplatin and how is it used?
Cisplatin is a platinum-based cytotoxic drug used intravenously to treat multiple cancers. FDA-labeled uses include testicular, ovarian, bladder, head and neck, lung, cervical, esophageal, gastric, prostate, and other malignancies, either as monotherapy or in combination regimens. The National Cancer Institute identifies cisplatin as one of the most widely used platinum chemotherapy agents (National Cancer Institute, n.d.).
Cisplatin is commonly administered in hospital or outpatient infusion settings. Its use requires hydration, renal monitoring, electrolyte management, antiemetic treatment, and laboratory surveillance because nephrotoxicity, ototoxicity, neurotoxicity, and severe nausea can limit treatment.
The commercial product is generally supplied as a sterile intravenous solution or concentrate in single-dose vials. Common strengths include 1 mg/mL, although vial sizes and presentations vary by manufacturer and jurisdiction.
Cisplatin’s clinical position
Cisplatin remains important despite the availability of carboplatin and newer targeted therapies because it has high activity in several curative-intent settings. It is a standard component of treatment for:
- Testicular cancer
- Bladder and urothelial cancer
- Head and neck cancer
- Non-small-cell and small-cell lung cancer
- Ovarian cancer
- Cervical cancer
- Certain pediatric and germ-cell tumors
Carboplatin is often substituted when renal toxicity, neuropathy, hearing damage, or patient frailty makes cisplatin unsuitable. That substitution creates therapeutic competition, but cisplatin retains a distinct role where higher platinum intensity or established curative protocols are required.
When did cisplatin lose patent exclusivity?
Cisplatin lost meaningful patent exclusivity decades ago. It is not a current branded specialty product protected by a live composition-of-matter patent. The original branded product, Platinol, was associated with Bristol-Myers Squibb and received U.S. approval in 1978 under NDA 018057, according to FDA product records and historical labeling.
The core commercial barriers are therefore regulatory and manufacturing barriers, not patent barriers.
| Exclusivity category |
Cisplatin status |
| Composition-of-matter patent |
Expired or commercially irrelevant |
| Formulation patent |
No material blocking formulation estate identified for standard cisplatin injection |
| Method-of-use patent |
No broad blocking method-of-use estate for labeled indications |
| FDA new-drug exclusivity |
Expired |
| Orphan exclusivity |
No current broad orphan exclusivity blocking generic use |
| Biosimilar exclusivity |
Not applicable |
| Generic competition |
Established |
| Current commercial moat |
Sterile manufacturing, supply reliability, procurement contracts, and quality compliance |
The early discovery and development history of cisplatin predates the current pharmaceutical patent lifecycle. The drug was identified as an anticancer agent in the 1960s and entered clinical use before today’s standard patent-term framework became commercially relevant (Rosenberg et al., 1969).
What is the Orange Book status of cisplatin?
Cisplatin is an established small-molecule drug supplied through generic abbreviated new drug applications. FDA Orange Book relevance is limited because the original branded exclusivity period has ended and standard cisplatin injection products generally do not depend on a current patent barrier.
The Orange Book identifies approved drug products, reference listed drugs, therapeutic equivalence information, patents, and exclusivity where applicable. For cisplatin, the commercially relevant issue is whether a particular generic presentation is approved as therapeutically equivalent to the applicable reference product, not whether a patent blocks market entry (U.S. Food and Drug Administration, n.d.-a).
Because generic sterile injectables may differ in vial configuration, concentration, labeling, and supplier, hospital buyers often evaluate products through formulary, quality, and supply criteria in addition to Orange Book equivalence.
Paragraph IV challenges
Paragraph IV litigation is not a meaningful current driver for standard cisplatin injection. A generic applicant could theoretically challenge a listed patent, but the absence of a commercially significant live patent estate makes a new patent-based entry dispute unlikely.
The competitive threat to incumbent cisplatin suppliers comes from:
- New abbreviated applications
- Contract-manufacturing expansion
- Hospital purchasing decisions
- Wholesaler substitution
- Temporary shortage-driven switching
- Re-entry by manufacturers after remediation or capacity expansion
How many patents cover cisplatin?
No meaningful number of active patents protects cisplatin as a molecule. Standard cisplatin injection is a mature generic product. Any surviving patents, if present for a particular product, would need to be assessed at the individual product and jurisdiction level and would not create a broad market monopoly over cisplatin therapy.
Potentially relevant patent categories could include:
- A specific formulation or stabilizer system.
- A delivery device or infusion system.
- A manufacturing or purification process.
- A combination regimen.
- A new indication or dosing schedule.
These categories do not generally prevent use of conventional cisplatin injection under established oncology protocols. They also do not create biosimilar-style interchangeability barriers because cisplatin is not a biologic.
What formulations are protected by cisplatin patents?
Conventional cisplatin injection has limited patent protection. The practical formulation constraints arise from chemical stability, concentration, container compatibility, light handling, storage, and sterile manufacturing requirements.
Cisplatin is supplied in aqueous formulations and requires careful control of product quality. Manufacturing sites must manage:
- Sterility assurance
- Endotoxin limits
- Particulate control
- Assay and impurity profile
- Container closure integrity
- Storage conditions
- Hazardous-drug handling
- Batch-release testing
A formulation patent would have limited commercial impact unless it offered a clinically meaningful advantage, such as improved stability, reduced preparation burden, reduced nephrotoxicity, or a differentiated delivery system. Standard hospital demand remains concentrated in conventional injectable presentations.
What is cisplatin’s FDA regulatory status?
Cisplatin is FDA-approved as an injectable anticancer drug. Its labeling includes major safety warnings involving renal toxicity, bone-marrow suppression, ototoxicity, peripheral neuropathy, hypersensitivity reactions, and severe gastrointestinal toxicity (DailyMed, n.d.).
The FDA regulatory profile is mature:
| Regulatory factor |
Status |
| Product type |
Small-molecule cytotoxic drug |
| Administration |
Intravenous |
| Approval pathway |
Original NDA and subsequent ANDAs |
| Generic pathway |
Abbreviated New Drug Application |
| Biosimilar pathway |
Not applicable |
| Therapeutic equivalence |
Product-specific generic approvals |
| Main regulatory risk |
Sterile manufacturing and supply continuity |
| Main clinical risk |
Renal, auditory, neurologic, and hematologic toxicity |
The FDA has identified cisplatin among oncology drugs affected by supply disruptions. Shortages have resulted from manufacturing interruptions, raw-material constraints, quality issues, and limited supplier redundancy (U.S. Food and Drug Administration, n.d.-b).
Why has cisplatin experienced supply shortages?
Cisplatin is vulnerable to shortages because it combines high clinical importance with low generic pricing and technically demanding sterile production. Manufacturers may have limited economic incentive to maintain redundant capacity for a product that sells at a low price per vial but requires high-compliance manufacturing infrastructure.
Shortage risk is amplified by:
- Few active manufacturers
- Concentrated API production
- Dependence on a small number of sterile-finish facilities
- Long regulatory lead times for new capacity
- Hospital inventory buffers that are too small for prolonged disruption
- Fixed-price purchasing contracts
- Low profitability after quality, labor, and compliance costs
- Demand spikes in oncology treatment cycles
The result is an unusual market structure: cisplatin has little patent risk but meaningful operational risk. A supplier with reliable capacity can gain hospital share during a shortage even without a differentiated formulation.
What is the financial trajectory for cisplatin?
Cisplatin’s financial trajectory is structurally flat to declining on a per-unit basis, with intermittent revenue increases caused by shortages, price corrections, or temporary supply gaps. It is not a high-growth pharmaceutical asset.
Revenue characteristics
Drug-specific revenue is rarely disclosed by generic manufacturers. Companies typically report revenue by segment, geography, or product portfolio rather than by individual injectable oncology drug. As a result, cisplatin sales cannot be reliably derived from public filings without proprietary prescription, hospital purchasing, or invoice data.
The economic profile is nevertheless clear:
| Financial driver |
Effect on cisplatin economics |
| Patent expiry |
Eliminated branded pricing power |
| Generic entry |
Reduced net price and increased substitution |
| Hospital tenders |
Compressed margins |
| Shortages |
Can increase spot pricing and supplier share |
| Manufacturing costs |
High relative to product price |
| Demand |
Stable, protocol-driven, and clinically persistent |
| Innovation |
Limited for conventional injection |
| Revenue visibility |
Low at individual-company level |
| Margin durability |
Dependent on capacity and quality performance |
Cisplatin revenue is therefore volume-dependent. Manufacturers can generate attractive portfolio value if they have efficient sterile plants, broad hospital contracts, and reliable distribution, but the product alone is unlikely to support specialty-pharmaceutical margins.
Market growth outlook
Unit demand should remain stable because cisplatin is embedded in established cancer treatment protocols and global cancer incidence continues to increase. Revenue growth is likely to lag oncology spending because:
- The molecule is generic.
- Alternative platinum drugs constrain pricing.
- New targeted therapies and immunotherapies may displace cisplatin in selected populations.
- Hospital procurement systems negotiate aggressively.
- Treatment regimens are increasingly personalized.
The strongest demand should remain in countries where generic chemotherapy is central to oncology care and where newer targeted medicines are less accessible.
Which companies compete in the cisplatin market?
The competitive field includes generic injectable manufacturers, specialty pharmaceutical companies, contract manufacturers, and regional suppliers. Historical and current suppliers have included companies such as Teva Pharmaceutical Industries, Hikma Pharmaceuticals, Fresenius Kabi, Pfizer-related Hospira operations, Accord Healthcare, Eugia, Cipla, and regional manufacturers, depending on market and product availability.
Supplier participation changes over time because manufacturers may discontinue low-volume presentations, suspend production, or re-enter after remediation. Hospital buyers often treat cisplatin as a portfolio product purchased alongside carboplatin, oxaliplatin, fluorouracil, paclitaxel, and other oncology injectables.
How does cisplatin compare with carboplatin?
| Factor |
Cisplatin |
Carboplatin |
| Commercial status |
Generic |
Generic |
| Main route |
Intravenous |
Intravenous |
| Renal toxicity |
Higher |
Generally lower |
| Ototoxicity and neuropathy |
More prominent |
Generally less prominent |
| Myelosuppression |
Clinically important |
Often more dose-limiting |
| Hydration burden |
Higher |
Lower |
| Curative protocols |
Strong role in several cancers |
Broad role, often for tolerability |
| Supply-chain risk |
Significant |
Also exposed to sterile-injectable risk |
| Patent risk |
Minimal |
Minimal |
Cisplatin and carboplatin compete clinically, but they are not perfect substitutes. Switching is constrained by cancer type, treatment intent, renal function, hearing status, performance status, and physician preference.
What patent litigation affects cisplatin?
There is no major current patent litigation affecting the standard cisplatin injection market. Litigation risk is more likely to arise from:
- Product liability claims
- Manufacturing-quality disputes
- Contract and supply disagreements
- Regulatory enforcement
- Procurement disputes
- Alleged shortages or allocation practices
A new formulation or delivery technology could create patent litigation, but such a dispute would concern the differentiated product rather than generic cisplatin itself.
What licensing deals involve cisplatin?
Cisplatin is not currently associated with a major exclusive licensing transaction comparable to those involving novel oncology drugs. Historical rights were tied to the development and commercialization of the original branded product. Current licensing activity is more likely to involve manufacturing, distribution, regional registration, or contract supply.
For investors and licensing teams, the relevant diligence points are:
- Whether the supplier owns or contracts its API source
- Whether the finished-dose facility is FDA-approved
- Whether the supplier has a reliable U.S. or European inspection record
- Whether the product is covered by long-term hospital contracts
- Whether a distributor has inventory and allocation rights
- Whether the supplier has an approved alternative presentation
What generic entry risks exist for cisplatin?
The principal generic-entry risk is not patent invalidation. It is operational oversupply followed by supplier exit, or entry by a new manufacturer that fails to achieve adequate scale.
A new entrant would face:
- FDA approval and inspection requirements.
- Validated sterile manufacturing.
- Cytotoxic handling infrastructure.
- API qualification.
- Hospital contracting and wholesaler access.
- Price pressure from incumbent suppliers.
- Working-capital requirements for inventory.
- Shortage-reporting and allocation obligations.
Generic entry can improve supply redundancy but may also reduce prices enough to weaken the economics of smaller manufacturers. The long-term market may support only a limited number of efficient suppliers despite strong clinical demand.
What is the geographic coverage of cisplatin?
Cisplatin is marketed globally, but regulatory and commercial availability varies by country. The United States, European Union, Japan, China, India, and other major markets have established use. Lower-income markets may depend heavily on generic supply and face greater exposure to stock-outs.
Geographic commercial value depends on:
- Local cancer incidence
- National reimbursement
- Public-hospital procurement
- Import dependence
- Local API production
- Regulatory registration
- Cold-chain and distribution infrastructure
- Availability of alternative platinum agents
India and China are important manufacturing and supply-chain centers for generic oncology medicines. The United States and Europe remain high-value markets because of hospital purchasing volumes, regulatory standards, and shortage sensitivity.
How strong is the cisplatin patent estate?
The patent estate is weak for conventional cisplatin injection and does not support premium pricing. The stronger competitive assets are manufacturing know-how, validated facilities, supplier qualification, regulatory history, and distribution.
| Asset |
Strategic strength |
| Core molecule patent |
None of practical commercial value |
| Standard injection formulation |
Weak |
| Method-of-use protection |
Weak |
| Regulatory approvals |
Moderate |
| Sterile manufacturing capacity |
Stronger than patent position |
| Hospital contracts |
Moderate |
| Supply reliability |
Potentially strong |
| Brand recognition |
Limited in generic market |
What are the likely generic launch scenarios?
Three scenarios define the market.
Stable-supply scenario
Multiple manufacturers maintain capacity, shortages remain limited, and prices stay low. Revenue grows with treatment volume but margins remain compressed.
Shortage-premium scenario
One or more suppliers experience manufacturing or API disruption. Remaining suppliers gain volume, hospitals accept higher prices, and distributors prioritize allocation. The benefit is temporary and may be offset by regulatory scrutiny and supply obligations.
Structural-contraction scenario
Low prices, compliance costs, and weak margins lead manufacturers to exit. The number of suppliers falls, creating recurring shortages and higher procurement volatility. This is the most important long-term risk for hospitals and public-health systems.
Key Takeaways
- Cisplatin is a mature, off-patent generic oncology drug.
- No meaningful current composition, formulation, or method-of-use patent blocks standard cisplatin injection.
- Paragraph IV litigation and biosimilar competition are not material market risks.
- Financial performance depends on volume, hospital contracts, manufacturing efficiency, and supply reliability.
- Public companies generally do not disclose cisplatin revenue separately.
- The major commercial risk is sterile-injectable shortage, not patent expiry.
- Carboplatin is the closest clinical competitor but does not fully replace cisplatin.
- New entrants face regulatory, manufacturing, API, and procurement barriers despite the absence of patent barriers.
- Long-term demand should remain clinically durable, while pricing power remains limited.
- A reliable supplier can obtain strategic value from cisplatin through portfolio breadth and shortage resilience rather than product differentiation.
FAQs
Is cisplatin still profitable for generic manufacturers?
Cisplatin can be profitable as part of a broader sterile-oncology portfolio, but standalone margins are constrained by low generic pricing, hospital tenders, quality costs, and competition.
Can a new company patent cisplatin?
A company generally cannot patent the old cisplatin molecule. It may seek patents for a genuinely novel formulation, manufacturing process, delivery system, or treatment method that meets patentability requirements.
Is cisplatin subject to biosimilar competition?
No. Cisplatin is a chemically synthesized small molecule, so competitors enter through generic-drug pathways rather than the biosimilar pathway.
Why is cisplatin sometimes unavailable if it is generic?
Generic status does not guarantee supply. Limited sterile capacity, API disruptions, manufacturing failures, and low commercial returns can produce shortages even when demand is stable.
Does carboplatin eliminate the need for cisplatin?
No. Carboplatin is often selected for tolerability, but cisplatin remains important in several curative and disease-specific regimens where clinical evidence and treatment protocols favor it.
References
DailyMed. (n.d.). Cisplatin injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
National Cancer Institute. (n.d.). Cisplatin. U.S. Department of Health and Human Services. https://www.cancer.gov/
Rosenberg, B., VanCamp, L., Trosko, J. E., & Mansour, V. H. (1969). Platinum compounds: A new class of potent antitumour agents. Nature, 222, 385-386. https://doi.org/10.1038/222385a0
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.-b). Drug shortages: Cisplatin injection. https://www.accessdata.fda.gov/scripts/drugshortages/
